Kamada is proud to be one of the supporting partners of the upcoming IDS congress.
The congress will include talks on a wide range of current topics of interest to the community, which include ground-breaking technologies, cell-based and advanced therapeutics, immunopathology of type 1 diabetes, pathways to beta cell failure, updates from the Networks – nPod, TEDDY, Trialnet and the Immune Tolerance Network, as well as an adversarial debate and a “balloon debate”. There will be ample opportunities for networking and discussion, to move towards our common goal of understanding the immunology of type 1 diabetes and how we may intervene to change the course of disease.
The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors.
Kamada CEO ,Amir London, will present on October 2 at 14:00.
The conference is a three-day multitrack event, which will feature over 200 innovative industry leaders from public and private companies for an in-depth discussion of the developments and trends shaping biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.
Kamada's CEO, Amir London, will present on: Wed, Oct 3 at 3:25-3:55 PM in Track 5 - Grand Ballroom 2.
ERS congress is the largest meeting of respiratory professionals in the world, with an outstanding scientific and educational programme designed to address the needs of researchers, clinicians, general practitioners and allied health professionals alike.
Covering key topics in respiratory medicine from across the spectrum of disease areas including TB, lung cancer, chronic and acute respiratory failure, sleep breathing disorders, interstitial lung diseases, pneumonia, cystic fibrosis, COPD and asthma, amongst others, the congress programme is set to deliver the best advances in both science and education.
This years’ congress will specifically highlight the importance of environment in respiratory health and focus on the need to personalise medicine in the respiratory arena. Special attention will also be paid to our interactions with microorganisms in our environment as well as those that live in peace within our organism.
The Scientific Sessions offers researchers and health care professionals an amazing opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Over the course of five days, attendees will receive exclusive access to more than 2,800 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand professional networks with nearly 13,000 professional attendees from around the world.
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.
Respiration Day is a highly scientific, international event, reserved to physicians and researchers who meet annually to exchange ideas and experiences and to be updated on the latest outcomes of the worldwide biomedical research in respiratory diseases. The aim of the 2018 edition of “Respiration Day” is to provide the view of where the Respiratory clinicians and researchers community is, and where it needs to go in the evolving era of personalized medicine.
The congress is expected to attract over 17,000 clinical investigators, scientists and medical professionals related to the fields of sleep medicine pulmonary, and critical care. Aimed at displaying and delivering the educational sessions about recent advancements in research related to Pneumology the conference will show-up as a benchmark and turning point for the medical personnel.
Oppenheimer Israel is the leading provider of global brokerage services to the Israeli Institutional market. The established Tel-Aviv based office is operating for more than 40 years and employs professionals in brokerage, research and executive services. Supported by the Oppenheimer USA group, Oppenheimer Israel services the leading Israeli financial institutions: Banks, Brokers, Insurance Companies, Pension funds, Hedge Funds, Mutual funds and Portfolio Managers.